calcium, potassium salt of (-)-hydroxycitric acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: calcium, potassium salt of (-)-hydroxycitric acid
• 英文别名: CaKHCA；Calcium;potassium;1,2-dihydroxypropane-1,2,3-tricarboxylate；calcium;potassium;1,2-dihydroxypropane-1,2,3-tricarboxylate
• 化学式: C₆H₅O₈*Ca*K
• 分子量: 284.277
• InChiKey: XFOSOYZCQOPDSQ-UHFFFAOYSA-K

计算性质

• 辛醇/水分配系数(LogP)：
  -9.66
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  161
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  calcium, potassium salt of (-)-hydroxycitric acid 、 D-氨基葡萄糖盐酸盐 以 甲醇 、 水 为溶剂， 反应 5.0h， 生成 calcium, glucosamine double salt of (-)-hydroxycitric acid
  参考文献：
  名称：

  Double salts of (-)-hydroxycitric acid with an amine and a group II a metal and a process for preparing the same

  摘要：

  这项发明涉及(-)-羟基柠檬酸与胺和锌或II A族金属的新型双盐。这些化合物稳定且水溶性，可用作保健品、减肥剂和饮料。双盐具有以下一般式(I)，其中X为锌或周期表II A族金属，Y为葡萄糖胺、咖啡因或已知的厌食胺残基。

  公开号：

  US20070027110A1
• 作为产物：
  描述：

  potassium hydroxide 、 Calcium;3-carboxy-2,3-dihydroxypentanedioate 以 水 为溶剂， 以63.5 g的产率得到calcium, potassium salt of (-)-hydroxycitric acid
  参考文献：
  名称：

  MONOMERIC BIMETAL HYDROXYCITRIC ACID COMPOUNDS AND METHODS OF MAKING AND USING THE SAME

  摘要：

  提供了单体双金属羟基柠檬酸（HCA）化合物。这些化合物包括一种二价金属（X）与C2和C3的羧酸结合，以及一种一价金属（Y）与C1的羧酸结合。还提供了从二聚起始物质（例如X3(HCA)2）制备所述化合物的方法，包括使二聚体酸化以产生单体中间体，随后用YOH碱中和。提供了缓解与目标疾病或症状相关的至少一个症状的方法。还提供了包括所述单体双金属HCA化合物的组合物，这些组合物在各种治疗应用中有用。

  公开号：

  US20180065992A1

文献信息

• Hydroxycitric acid compounds and capsule liquid delivery
  申请人：GLYKON TECHNOLOGIES GROUP, LLC

  公开号：US10561630B2

  公开（公告）日：2020-02-18

  A capsule oral delivery system is disclosed. The system includes an outer capsule completely enclosing an inner content, or a hard shell comprised of hydroxypropyl methylcellulose (HPMC) enclosing the content. A liquid formulation forming the inner content of the outer capsule is comprised of a hydroxycitric acid (HCA) salt, water, and glycerol, with the HCA being completely dissolved in the water and glycerol which may be the only components present in the capsule, which may be administered to a patient in a method of treatment to cause weight loss when repeatedly administered.

  本发明公开了一种胶囊口服给药系统。 该系统包括一个完全包裹内含物的外胶囊，或一个包裹内含物的由羟丙基甲基纤维素（HPMC）组成的硬壳。 构成外层胶囊内部内容物的液体配方由羟基柠檬酸（HCA）盐、水和甘油组成，其中羟基柠檬酸完全溶解在水和甘油中，而水和甘油可能是胶囊中存在的唯一成分，在反复给药的治疗方法中，可将其给患者服用，以达到减肥的目的。
• (-)-Hydroxycitric acid for the modulation of angiotensin-converting enzyme
  申请人：Clouatre L. Dallas

  公开号：US20060025482A1

  公开（公告）日：2006-02-02

  The invention teaches that supplementation with (−)-hydroxycitrate constitutes a novel means of modulating the angiotensin-converting enzyme (ACE)/renin-angiotensin-aldosterone system and is useful for preventing, treating and ameliorating conditions involving the angiotensin-converting enzyme (ACE)/renin-angiotensin-aldosterone system. The discovery that HCA has angiotensin-converting enzyme (ACE)/renin-angiotensin-aldosterone system-moderating effects allows for the creation of novel and more efficacious approaches to preventing and ameliorating conditions that arise from excessive ACE activity. These include cardiovascular diseases in general, heart failure, ventricular remodeling, ejection fraction issues, atrial fibrillation, and a wide variety of renal conditions. Other health conditions discovered to be influenced by the angiotensin-converting enzyme (ACE)/renin-angiotensin-aldosterone system would similarly be expected to be influenced. It is yet a further advantage of the present invention to provide a means—one that is accompanied by few or no side effects—of maintaining such improved status without resort to special diets. Furthermore, this discovery makes possible the development of adjuvant modalities that can be used to improve the results realized with other treatment compounds while at the same time reducing the side effects normally found with such drugs. HCA delivered in the form of its potassium salt is efficacious at a daily dosage (bid or tid) of between 750 mg and 10 grams, preferably at a dosage of between 3 and 6 grams for most individuals. A daily dosage above 10 grams might prove desirable under some circumstances, such as with extremely large or resistant individuals, but this level of intake is not deemed necessary under normal conditions.

  本发明表明，补充(-)-羟基柠檬酸盐是调节血管紧张素转换酶（ACE）/肾素-血管紧张素-醛固酮系统的一种新方法，可用于预防、治疗和改善涉及血管紧张素转换酶（ACE）/肾素-血管紧张素-醛固酮系统的病症。发现 HCA 具有血管紧张素转换酶（ACE）/肾素-血管紧张素-醛固酮系统的调节作用后，就能创造出更有效的新方法来预防和改善因 ACE 活性过高而引起的疾病。这些疾病包括心血管疾病、心力衰竭、心室重塑、射血分数问题、心房颤动以及各种肾脏疾病。其他被发现受血管紧张素转换酶（ACE）/肾素-血管紧张素-醛固酮系统影响的健康状况也会受到类似的影响。本发明的另一个优点是提供了一种几乎没有副作用的方法，无需借助特殊饮食就能保持这种改善的状态。此外，本发明还有助于开发辅助方法，用于改善其他治疗化合物的效果，同时减少这些药物通常会产生的副作用。以钾盐形式提供的 HCA 每日用量（bid 或 tid）在 750 毫克到 10 克之间，对大多数人来说最好在 3 克到 6 克之间。在某些情况下，如体型巨大或抵抗力极强的人，每天摄入 10 克以上的剂量可能是可取的，但在正常情况下，这种摄入量被认为是不必要的。
• (-)-Hydroxycitric acid for protection against soft tissue and arterial calcification
  申请人：Clouatre L. Dallas

  公开号：US20060025483A1

  公开（公告）日：2006-02-02

  The inventor has discovered that supplementation with (−)-hydroxycitric acid, its salts and related compounds constitutes a novel means of inhibiting, reducing and regulating calcification of the blood vessels and other soft tissues and is useful for preventing, treating and ameliorating conditions involving soft tissue calcification. Such regulation offers benefits against arterial calcification and vascular diseases, osteoarthritis, rheumatoid arthritis, the calcification of surgical stints, such as those containing elastin. These benefits of HCA are especially pronounced with the use of the preferred salts of the acid, potassium hydroxycitrate and potassium-magnesium hydroxycitrate, and may be further potentiated by the use of a controlled-release form of the compound. The discovery that HCA has calcium-regulating effects in the soft tissues allows for the creation of novel and more efficacious approaches to preventing and ameliorating cardiovascular diseases, arthritis and a variety of other conditions. Inasmuch as one element common to advancing years is an increased level of generalized calcification of the soft tissues, the invention lends itself to reducing or delaying this aspect of aging. Furthermore, this discovery makes possible the development of adjuvant modalities that can be used to improve the results realized with other treatment compounds while at the same time reducing the side effects normally found with such drugs. HCA delivered in the form of its potassium salt is efficacious at a daily dosage (bid or tid) of between 750 mg and 10 grams, preferably at a dosage of between 3 and 6 grams for most individuals. A daily dosage above 10 grams might prove desirable under some circumstances, such as with extremely large or resistant individuals, but this level of intake is not deemed necessary under normal conditions.

  本发明者发现，补充(-)-羟基柠檬酸、其盐类和相关化合物是抑制、减少和调节血管及其他软组织钙化的一种新方法，可用于预防、治疗和改善涉及软组织钙化的病症。这种调节可防治动脉钙化和血管疾病、骨关节炎、类风湿性关节炎、外科缝合线（如含有弹性蛋白的缝合线）的钙化。使用羟基柠檬酸钾和羟基柠檬酸钾镁这两种优选的酸盐时，HCA 的这些益处尤为明显，使用控释形式的化合物可进一步增强其功效。HCA 在软组织中具有钙调节作用，这一发现为预防和改善心血管疾病、关节炎和其他多种疾病提供了新颖、更有效的方法。随着年龄的增长，软组织普遍钙化的程度也会增加，因此本发明可以减少或延缓这方面的衰老。此外，这一发现还使辅助治疗方法的开发成为可能，这些辅助治疗方法可用于改善其他治疗化合物的效果，同时减少此类药物通常会产生的副作用。以钾盐形式提供的 HCA 每日用量（bid 或 tid）在 750 毫克到 10 克之间，对大多数人来说最好在 3 克到 6 克之间。在某些情况下，如体型巨大或抵抗力极强的人，每天摄入 10 克以上的剂量可能是可取的，但在正常情况下，这种摄入量被认为是不必要的。
• SYNERGISTIC COMBINATION TO ENHANCE BLOOD GLUCOSE AND INSULIN METABOLISM
  申请人：Glykon Technologies Group, Llc.

  公开号：EP2445338A1

  公开（公告）日：2012-05-02
• Synergistic combination to enhance blood glucose and insulin metabolism
  申请人：Clouatre Daniel Elliot

  公开号：US20100323031A1

  公开（公告）日：2010-12-23

  The present disclosure discloses a synergistic combination comprising (−)-hydroxycitric acid, bitter melon extract and sesame seed lignans extract to enhance blood glucose and insulin metabolism. The synergistic combination also reduces reactive hypoglycemia in those who are insulin resistant.